Anzeige
Meldung des Tages: Auftakt zu Maßnahmen: Grundlegendes Material für die Verteidigungsindustrie der USA wird immer wichtiger

Genprex Aktie News

Aktie
WKN:  A41L3N ISIN:  US3724463027 US-Symbol:  GNPX Branche:  Biotechnologie Land:  USA
0,18 €
+0,00 €
0,00%
21.10.25
Depot/Watchlist
Marktkapitalisierung *
1,90 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Genprex News

30.04.25 - PR Newswire
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual ...
29.04.25 - PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting PR Newswire
28.04.25 - PR Newswire
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma PR Newswire
24.04.25 - PR Newswire
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting PR Newswire
22.04.25 - PR Newswire
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings PR Newswire
26.03.25 - PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting PR Newswire
25.03.25 - PR Newswire
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions PR Newswire
04.03.25 - PR Newswire
Genprex to Participate at BIO Europe Spring 2025
Genprex to Participate at BIO Europe Spring 2025 PR Newswire
19.02.25 - PR Newswire
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System PR Newswire
18.02.25 - PR Newswire
Genprex Provides Update on Diabetes Gene Therapy Program
Genprex Provides Update on Diabetes Gene Therapy Program PR Newswire
13.02.25 - PR Newswire
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer PR Newswire

Newssuche

Videos

newspaper
02.02.26 -7,76%
Technical Trading Silber Crash!
Silber Short Typ: Turbo Open End WKN: VJ4GQU Hebel: 3,77 Laufzeit: OpenEnd Einstieg: Market ... Mehr »